GW Pharmaceuticals Presents Positive Results of Epidiolex

GW Pharmaceuticals recently presented positive results from two Phase 3 clinical trials evaluating its lead cannabidiol therapeutic candidate, Epidiolex, in patients with lennox-gastaut syndrome (LGS) and Dravet syndrome (DS), two treatment-resistant epilepsy syndromes. The presentations took place during the American Epilepsy Society (AES) Annual Meeting in Houston, Texas Dec. 2-6.

Epidiolex is an oral formulation of pure plant-derived cannabidiol (CBD), being initially developed for severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, LGS, tuberous sclerosis complex (TSC) and infantile spasms (IS). The drug has both Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) in the treatment of Dravet syndrome, for which there are no treatments approved in the United States.

“We are very excited to share these data from our Phase 3 programs with the epilepsy community. These presentations are the culmination of intensive effort by the GW in-house team and more than

... read more at: